Non Small Cell Lung Cancer Clinical Trial
Official title:
Assessment of Surgical Mediastinal sTaging in cN1 Lung canceR
In case of PET or CT based cN1 (suspected) NSCLC, ESTS guidelines propose mediastinal staging by echo-endoscopy OR mediastinoscopy. Recent data show a sensitivity of less than 50% for echo-endoscopy to detect N2 disease in cN1 NSCLC patients, while prevalence of mediastinal nodal disease was 24% (unpublished data Aster II).2 The investigators plan to perform a prospective multicentric observational study to measure the sensitivity of mediastinal staging by video-assisted mediastinoscopy (VAM) in cN1 operable and resectable (suspected) NSCLC patients.
Few reports in the literature evaluated the final pathological stage distribution of patients
with resectable and operable non-small cell lung cancer (NSCLC) with clinical stage cN1.
These retrospective series demonstrated that patients with computed tomography (CT) based cN1
often had clinically occult mediastinal lymph node metastases (N2/3 disease). Hishida et al.
reported that 30% of 143 patients with cN1 were diagnosed N2/3 by mediastinoscopy3. Watanabe
et al. reported that 37% of 168 patients with cN1 were diagnosed N2/3 by mediastinoscopy 4.
Adding FDG-positron emission tomography (PET) to CT might enable the detection of N2/3
disease among these cN1 patients, but negative PET findings do not necessarily exclude N2/3
disease. Kim et al reported that 19,2 % of 99 patients with cN1, in whom cN2 was ruled out by
PET-CT scan, were found to have pathologic N2 disease at pulmonary resection with mediastinal
lymph node dissection.5 In conclusion, 20-30% of patients with cN1 nodes on imaging, and
normal sized FDG-negative mediastinal lymph nodes on CT and PET have malignant involvement in
their mediastinal nodes.
The ACCP guidelines state that invasive preoperative mediastinal staging should be performed
in these cN1 patients 6. The updated ESTS guidelines recommend mediastinal staging by
echo-endoscopic or mediastinoscopy.1 Non-randomized trials suggested the potential of linear
endosonography for mediastinal staging 7-9. However, the patients with cN1 disease form only
a minority in these studies. A recently performed prospective ASTER 2 trial (N=100) showed a
sensitivity of echo-endoscopic for mediastinal staging of 38% (ITT analysis), while the
prevalence of mediastinal nodal disease was 24% (unpublished data Aster 2) 2. The conclusion
made by ASTER 2 is that a negative endosonography must be followed by a VAM. However, the
investigators consider such double approach not cost-effective in a setting with N2
prevalence <30%. Therefore, it seems reasonable to perform a VAM instead of an endosonography
in cN1 patients, which is one of the proposed strategies in the recent ESTS guidelines.1
However, there is no prospective study to date that assessed the sensitivity, NPV and
accuracy of VAM in a well-defined group of cN1 patients.
Several publications have demonstrated a lobe-specific mediastinal nodal drainage for upper
versus lower lobe NSCLC. Shapiro et al conclude that in early lung cancer, including cN1
disease, lobe-specific mediastinal dissection is warranted 10. However, in this study the
only patient with a positive subcarinal node, upper lobe tumour, and negative superior
mediastinal nodes had positive N1 nodes. To the investigators knowledge there is no study
focussing on mediastinal nodal dissemination patterns in cN1 patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |